Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha TeknovaTKNO +0.56%63 Gross Margin % is 34.16% as of Mar. 2026, which is 19% below its 10-year median of 42.19. GuruFocus rates TKNO with a GF Score™ of 63/100 and a GF Value™ of $3.55 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 941 Drug Manufacturers companies, Alpha Teknova ranks worse than 75.56% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Alpha Teknova had a gross margin of 34.16% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Alpha Teknova Gross Margin % Related Terms
Alpha Teknova Gross Margin % Historical Data
* Premium members only.
The historical data trend for Alpha Teknova's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TKNO vs AKBA, ORGO, SIGA: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Teknova Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Alpha Teknova's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Alpha Teknova (TKNO) has a Gross Margin % of 34.16% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Alpha Teknova and its competitors. This is 19% below median its historical median of 42.19. Over the past decade, Alpha Teknova's Gross Margin % has ranged from 19.16 to 56.73. According to the industry distribution chart, Alpha Teknova ranks #711 out of 941 companies in the Drug Manufacturers industry, placing it in the top 75.6%.
Is Alpha Teknova's Gross Margin % too high?
Alpha Teknova's current Gross Margin % of 34.16% is 19% below median its 10-year median of 42.19. Over the past 10 years, this metric has ranged from a low of 19.16 to a high of 56.73. The Drug Manufacturers industry median Gross Margin % is 48.54. Alpha Teknova's value of 34.16% is 29.6% below this industry median. Based on the distribution chart, Alpha Teknova ranks #711 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alpha Teknova has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's Gross Margin % compare to AKBA and ORGO?
According to the Drug Manufacturers industry distribution chart, Alpha Teknova ranks #711 out of 941 companies for Gross Margin %. This places Alpha Teknova in the lower half of its industry. The industry median Gross Margin % is 48.54. Alpha Teknova's value of 34.16% is 29.6% below this benchmark. Historically, Alpha Teknova's own Gross Margin % has ranged from 19.16 to 56.73 over the past decade. While the company's 10-year median is 42.19 vs. the industry median of 48.54, Alpha Teknova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Teknova's current Gross Margin % of 34.16% is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Alpha Teknova and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current Gross Margin % is 34.16%, which is 19% below median its own 10-year median of 42.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.55, compared to a current price of $5.34 — trading 50.4% above its estimated fair value. The current Gross Margin % is 34.16%, which is 19% below median its 10-year median of 42.19 and 29.6% below the Drug Manufacturers industry median of 48.54. Alpha Teknova's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current Gross Margin % is 34.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $5.34 is trading 50.4% above its estimated GF Value™ of $3.55.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
Gross Margin %: 34.16% (19% below median its 10-year median of 42.19)
GF Value™: $3.55 vs. price of $5.34 (50.4% above fair value)
Industry Position: 29.6% below the Drug Manufacturers median (#711 of 941)
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
63GF Score
Get the complete analysis for TKNO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
